OSCR

Ultrasound-triggered platelet vehicles loading fluorescein for targeted sonodynamic therapy of glioblastoma.

Overview

Authors: Yu-Xin Guo1, Qing Deng1,2, Ke Li2, Quan Zhang3, Jie Guo4, Meng-Fei Wang4, Jia-Lin Wu4, Hui-Mei Lei4, Yue-Ying Chen1, Huan Pu1, Yu-fan Gao5, Yong-Hong Xu6, Xiao Chen4,7, Qing Zhou1
  1. Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, China
  2. Center for Lab Teaching, School of Basic Medical Sciences, Wuhan University, Wuhan, China
  3. Department of Anatomy and Embryology, School of Basic Medical Sciences, Wuhan University, Wuhan, China
  4. Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan, China
  5. Department of Radiology, Renmin Hospital of Wuhan University, Wuhan, China
  6. Institute of Ophthalmological Research, Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, China
  7. Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China
Journal: Drug delivery, volume 33, issue 1, article 2708389
Dates: received 22 December 2025; accepted 20 July 2026; published online 29 July 2026; in print December 2026
Type: Research article · Language: English
License: CC BY-NC
Identifiers: DOI 10.1080/10717544.2026.2708389 · PMID 42523098 · PMCID PMC13421115 · OpenAlex W7171745771
Open access: gold, a free copy (OpenAlex)
Categories: other (modality), human (organism), mouse (organism), other condition (population), clinical / translational (subfield)
Methods: Statistics
Keywords: Fluorescein, Platelets, Glioblastoma, hypoxia-inducible factor-1, Sonodynamic Therapy
MeSH: Blood Platelets*, Brain Neoplasms*, Fluorescein*, Glioblastoma*, Ultrasonic Therapy*, Animals, Blood-Brain Barrier, Cell Line, Tumor, Drug Delivery Systems, Humans, Mice, Mice, Nude, Probenecid, Ultrasonic Waves (* major topic)
Topic: Ultrasound and Hyperthermia Applications (Biomedical Engineering, Engineering), according to OpenAlex
Funding: The Interdisciplinary Innovative Talents Foundation from Renmin Hospital of Wuhan University (JCRCFZ-2022-004); National Natural Science Foundation of China (82271999)
Citations: not cited yet (Europe PMC); 47 references in the paper

Abstract

Glioblastoma (GBM), the deadliest primary brain malignancy, resists treatment because of the blood‒brain barrier (BBB) and intrinsic resistance mechanisms. Fluorescein (FL), a clinically approved fluorophore, shows promise as a sonosensitizer for sonodynamic therapy (SDT), but faces challenges in tumor delivery and incomplete mechanistic understanding beyond ROS-mediated damage. We developed a bioinspired platelet-based delivery platform exploiting the natural tumor-homing properties of platelets for targeted FL delivery. Platelets were loaded with fluorescein diacetate (FDA), a lipophilic prodrug that is converted intracellularly to active FL, combined with probenecid to inhibit MRP1-mediated efflux, generating the ultrasound-responsive vitro, FL demonstrated sonocytotoxicity; upon low-intensity ultrasound, rapidly released FL into GBM cells, producing significant cytotoxicity enhanced by probenecid-mediated retention. In subcutaneous and orthotopic mouse models, intravenous with probenecid and sequential ultrasound achieved extensive tumor FL accumulation, massive necrosis, significant growth inhibition, and prolonged survival. Mechanistically, FL-SDT induces DNA damage while promoting HIF-1α degradation via the ubiquitin‒proteasome and autophagy‒lysosome pathways, thus suppressing downstream DNA repair enzymes (SMUG1 and LIG4). This dual mechanism combines direct genotoxicity with impaired DNA repair capacity, underlying the potent anti-GBM efficacy. Our platelet-based FL delivery represents a practical, safe, translational therapy for overcoming BBB limitations by disabling HIF-1α-regulated DNA repair

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 14 authors, 5 keywords, 14 MeSH terms, 2 funders, 47 references.

Cite

This paper

Guo, Y.-X., Deng, Q., Li, K., Zhang, Q., Guo, J., Wang, M.-F., Wu, J.-L., Lei, H.-M., Chen, Y.-Y., Pu, H., Gao, Y.-f., Xu, Y.-H., Chen, X., & Zhou, Q. (2026). Ultrasound-triggered platelet vehicles loading fluorescein for targeted sonodynamic therapy of glioblastoma. Drug delivery, 33(1), 2708389. https://doi.org/10.1080/10717544.2026.2708389

BibTeX

@article{guo2026ultrasound,
author = {Guo, Yu-Xin and Deng, Qing and Li, Ke and Zhang, Quan and Guo, Jie and Wang, Meng-Fei and Wu, Jia-Lin and Lei, Hui-Mei and Chen, Yue-Ying and Pu, Huan and Gao, Yu-fan and Xu, Yong-Hong and Chen, Xiao and Zhou, Qing},
title = {{Ultrasound-triggered platelet vehicles loading fluorescein for targeted sonodynamic therapy of glioblastoma}},
journal = {Drug delivery},
year = {2026},
month = jul,
volume = {33},
number = {1},
pages = {2708389},
publisher = {Taylor \& Francis},
issn = {1071-7544},
doi = {10.1080/10717544.2026.2708389},
url = {https://doi.org/10.1080/10717544.2026.2708389},
pmid = {42523098},
pmcid = {PMC13421115}
}

RIS

TY - JOUR
AU - Guo, Yu-Xin
AU - Deng, Qing
AU - Li, Ke
AU - Zhang, Quan
AU - Guo, Jie
AU - Wang, Meng-Fei
AU - Wu, Jia-Lin
AU - Lei, Hui-Mei
AU - Chen, Yue-Ying
AU - Pu, Huan
AU - Gao, Yu-fan
AU - Xu, Yong-Hong
AU - Chen, Xiao
AU - Zhou, Qing
TI - Ultrasound-triggered platelet vehicles loading fluorescein for targeted sonodynamic therapy of glioblastoma
T2 - Drug delivery
J2 - Drug Deliv
PY - 2026
DA - 2026/07/29
VL - 33
IS - 1
SP - 2708389
SN - 1071-7544
PB - Taylor & Francis
DO - 10.1080/10717544.2026.2708389
UR - https://doi.org/10.1080/10717544.2026.2708389
LA - en
ER -

CSL-JSON

{
"id": "10.1080/10717544.2026.2708389",
"type": "article-journal",
"title": "Ultrasound-triggered platelet vehicles loading fluorescein for targeted sonodynamic therapy of glioblastoma",
"container-title": "Drug delivery",
"author": [
{
"family": "Guo",
"given": "Yu-Xin"
},
{
"family": "Deng",
"given": "Qing"
},
{
"family": "Li",
"given": "Ke"
},
{
"family": "Zhang",
"given": "Quan"
},
{
"family": "Guo",
"given": "Jie"
},
{
"family": "Wang",
"given": "Meng-Fei"
},
{
"family": "Wu",
"given": "Jia-Lin"
},
{
"family": "Lei",
"given": "Hui-Mei"
},
{
"family": "Chen",
"given": "Yue-Ying"
},
{
"family": "Pu",
"given": "Huan"
},
{
"family": "Gao",
"given": "Yu-fan"
},
{
"family": "Xu",
"given": "Yong-Hong"
},
{
"family": "Chen",
"given": "Xiao"
},
{
"family": "Zhou",
"given": "Qing"
}
],
"container-title-short": "Drug Deliv",
"volume": "33",
"issue": "1",
"page": "2708389",
"DOI": "10.1080/10717544.2026.2708389",
"PMID": "42523098",
"PMCID": "PMC13421115",
"ISSN": "1071-7544",
"publisher": "Taylor & Francis",
"URL": "https://doi.org/10.1080/10717544.2026.2708389",
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
29
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3390/molecules29061264 [code]
Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules.
Journal: Molecules (Basel, Switzerland)
In common: other condition, 2 references
[2] doi:10.3390/biomedicines13051177
Transposable Element Is Predictive of Chemotherapy- and Immunotherapy-Related Overall Survival in Glioma.
Journal: Biomedicines
In common: clinical / translational, other condition, 1 reference
[3] doi:10.1080/07853890.2024.2405079
Necroptosis-based glioblastoma prognostic subtypes: implications for TME remodeling and therapy response.
Journal: Annals of medicine
In common: clinical / translational, other condition, 1 reference
[4] doi:10.1038/s41598-025-26109-7
6-Gingerol enhances the anti-tumor activity of temozolomide by inhibiting EGR1/GDF15 signaling in glioblastoma.
Journal: Scientific reports
In common: other condition, mouse, 1 reference
[5] doi:10.1002/brb3.71701
POFUT1 Serves as an Independent Prognostic Factor and Therapeutic Target by Activating the PI3K/AKT Pathway in Glioma.
Journal: Brain and behavior
In common: clinical / translational, other condition, mouse, 1 reference
[6] doi:10.3390/cells14020066
Comprehensive Analysis Identifies <i>THEMIS2</i> as a Potential Prognostic and Immunological Biomarker in Glioblastoma.
Journal: Cells
In common: clinical / translational, other condition, mouse, 1 reference
[7] doi:10.1186/s10020-024-00857-0
Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis.
Journal: Molecular medicine (Cambridge, Mass.)
In common: clinical / translational, other condition, mouse, 1 reference
[8] doi:10.3390/medicina62061169 [code]
Survival Outcomes and Machine Learning-Based Prediction of 12-Month Mortality in Glioblastoma Before and During the COVID-19 Pandemic: A SEER Population-Based Study.
Journal: Medicina (Kaunas, Lithuania)
In common: clinical / translational, other condition, 1 reference
[9] doi:10.1021/acs.jmedchem.6c00035
The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of &lt;i&gt;MTAP&lt;/i&gt;-Deleted Cancers.
Journal: Journal of medicinal chemistry
In common: other condition, mouse, 1 reference
[10] doi:10.1080/10717544.2026.2660007
Angiopep-2-decorated bacterial outer membrane vesicles penetrate the blood-brain barrier for glioblastoma chemo-immunotherapy.
Journal: Drug delivery
In common: other condition, mouse, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.